Health Canada has approved GSK's Hibsago (bepirovirsen) for chronic hepatitis B, marking another regulatory win for the drug. This approval expands the drug's market access, following previous authorizations in the US and Japan, and is a positive development for GSK and its partner Ionis Pharmaceuticals.
Health Canada has approved GSK's Hibsago (bepirovirsen) for the treatment of chronic hepatitis B in adults. This is a significant regulatory milestone for GSK, as it expands the commercial reach of a key drug, following prior approvals in the US and Japan. The approval is positive for GSK as it opens up the Canadian market, and also for Ionis Pharmaceuticals, which licensed the drug to GSK and collaborated on its development. While the drug won't be available until early 2027, this approval de-risks future revenue streams and strengthens GSK's infectious disease portfolio. For traders, this represents a long-term positive for GSK and IONS, indicating successful R&D and market expansion, though the immediate stock impact may be moderate given the delayed market entry.